clinical trial · NCT07870330
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children
ModernaTX, Inc.·phase1·recruiting·n = 96
Seasonal InfluenzamRNA-1010Fluarix Trivalent
brief summary
The purpose of this study is to evaluate safety, reactogenicity, and immunogenicity of mRNA-1010 in healthy children (9 to \<18 years of age).
started
Oct 7, 2026
primary completion
Dec 7, 2027
completion
Dec 7, 2027
last updated
Oct 28, 2026
official title
A Phase 1, Dose-escalation, Blinded Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children (9 to <18 Years of Age)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol